Addex Therapeutics Ltd (ADXN) Stock Analysis & Investment Frameworks

Addex Therapeutics Ltd (ADXN) stock analysis on Invetso. Review Addex Therapeutics Ltd’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Addex Therapeutics Ltd Company Overview

Addex Therapeutics Ltd Key Financial Metrics

About Addex Therapeutics Ltd

Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.

Addex Therapeutics Ltd Investment Frameworks

Invetso analyzes Addex Therapeutics Ltd (ADXN) across the following frameworks:

Explore More ADXN Research